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Available online 27 February 2016Treatment of disseminated tuberculosis in children ≤ 6 years has not been optimized. The pyrazinamide-
containing combination regimen used to treat disseminated tuberculosis in babies and toddlers was extrapolated
from adult pulmonary tuberculosis. Due to hepatotoxicity worries, there are no dose–response studies in chil-
dren. We designed a hollow ﬁber system model of disseminated intracellular tuberculosis with co-perfused
three-dimensional organotypic liver modules to simultaneously test for efﬁcacy and toxicity.We utilized pediat-
ric pharmacokinetics of pyrazinamide and acetaminophen to determine dose-dependent pyrazinamide efﬁcacy
and hepatotoxicity. Acetaminophen concentrations that cause hepatotoxicity in children led to elevated liver
function tests, while 100mg/kg pyrazinamide did not. Surprisingly, pyrazinamide did not kill intracellularMyco-
bacterium tuberculosis up to fourfold the standard dose as monotherapy or as combination therapy, despite
achieving high intracellular concentrations. Host-pathogen RNA-sequencing revealed lack of a pyrazinamide ex-
posure transcript signature in intracellular bacteria or of phagolysosomeacidiﬁcation on pH imaging. Artiﬁcial in-
telligence algorithms conﬁrmed that pyrazinamide was not predictive of good clinical outcomes in
children ≤ 6 years who had extrapulmonary tuberculosis. Thus, adding a drug that works inside macrophages
could beneﬁt children with disseminated tuberculosis. Our in vitro model can be used to identify such new reg-
imens that could accelerate cure while minimizing toxicity.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Recent estimates are that onemillion children developed tuberculo-
sis (TB) in 2010 alone (Jenkins et al., 2014). In babies and toddlers, TB
manifests as disseminated disease, attributed to poor immune contain-
ment (Newton et al., 2008). In disseminated disease,Mycobacterium tu-
berculosis (Mtb) is predominantly intracellular as opposed to the
predominantly extracellular bacteria in cavitary pneumonia in adults.
However, therapeutic regimens used to treat pediatric TB were copied
from those for adults with pulmonary TB. For multi-drug resistant TB
(MDR-TB) and extensively drug-resistant TB in children, no regimens
have been developed as of yet and in some parts of the world such chil-
dren are left untreated, and have been deemed “invisible” (Becerra and
Swaminathan, 2014; Dheda et al., 2014). There has been reluctance to
perform dose–response studies and ﬁrst in human studies in childrenses Research and Experimental
eet, Dallas, TX 75204, USA.
umbo).
. This is an open access article underbecause of concerns for toxicity such as drug induced liver injury
(DILI). Indeed, the incidence of DILI among children treated for TB
ranges between 1.7–8%, making this a legitimate concern (Devrim
et al., 2010; Roy et al., 2006) Recently, the World Health Organization
and STOP-TB have advocated for the design of new and shorter treat-
ment regimens for children, leading to zero TB deaths in children.
Thus the problem is pressing. Recently Momper et al. (2015) summa-
rized reasons for failed clinical trials in all pediatric drug development
asmainly due to lack of efﬁcacy, poor dosing, or toxicity; they proposed
use of pre-clinicalmodels to tackle these failures so that results could be
directly translated to the clinic. No pre-clinical model of intracellular TB
has been designed as of yet. On the other hand, preclinical toxicity re-
quiresmultiple animalmodel species testing. Regardless, rodentmodels
which are commonly used as one of the animals'models have predictive
rates of less than 40% for human DILI and resulted in second highest dis-
continuation rates for several drugs (Olson et al., 2000). In “Preventing
drug-induced liver injury: how useful are animal models?” Ballet argues
that no animal models are useful for predicting the most common
forms of human DILI at all and that humans themselves are best modelsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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which human concentration-time proﬁles of pharmaceuticals are ex-
amined exists as of yet. Here, we designed a model of intracellular TB,
ﬁtted a 3-dimensional human organoid liver (3D-liver), and dialed
human pediatric-like pharmacokinetics, for performance of pediatric
dose–response studies to estimate both safety and DILI at the same
time.
One of the pivotal drugs in the regimen used to treat children with
both drug-susceptible and MDR-TB, based on equivalent use in adults,
is pyrazinamide (Donald et al., 2012). The doses for use in children are
as yet unclear; based on computer aided clinical trial simulations we
and others have proposed that the doses be doubled for children with
pulmonary disease (Gumbo et al., 2009a; Thee et al., 2011). However,
this could lead to more DILI. On the other hand, there has been a debate
as to whether pyrazinamide kills intracellularMtb at all even in adults
(Crowle et al., 1991; Gumbo et al., 2009a). Contrariwise, it has been ar-
gued that pyrazinamide could work as an immunomodulatory agent in
the context of interferon-gamma (IFN-γ) secretion in granulomas
(Ahmad et al., 2011). If the former assertion is correct, pyrazinamide
as used currently in children with disseminated disease would not con-
tribute to efﬁcacy of the regimen. However, if the immunomodulatory
effect hypothesis is correct, then pyrazinamide could be a vital compo-
nent of treatment for disseminated TB. Here, we examined the efﬁcacy
and toxicity of pyrazinamide in our novel model for disseminated pedi-
atric disease, and found that the drug does not kill intracellularMtb even
when IFN-γ and tumor necrosis factor α (TNF-α) are supplemented.
Moreover, novel host-pathogen RNA sequencing (RNA-Seq) revealed
no transcriptomic or immunological signature of pyrazinamide
exposure.
2. Materials and Methods
2.1. Bacterial Strain and Growth Conditions
Prior to each experiment stockMtb culture (H37Ra, ATCC# 25177;
H37Rv ATCC# 27294) was thawed and grown in Middlebrook 7H9
broth supplemented with 10% oleic acid-dextrose-catalase (OADC) at
37 °C under 5% CO2 and shaking conditions. For the pH 5.8 studies the
log-phase growth bacteria were further cultured for 4 more days in
Middlebrook 7H9 broth acidiﬁed and buffered to a pH of 5.8, as de-
scribed in the past (Gumbo et al., 2009a).
2.2. Tissue Culture
Human derived THP-1 cell line (ATCC TIB-202) and murine macro-
phage cell line (J774A.1, ATCC TIB-67)were grown in RPMI-1640medi-
um supplemented with 10% fetal bovine serum (FBS) at 37 °C under 5%
CO2.
2.3. Reagents and Supplies
Hollow ﬁber system (HFS) cartridges were purchased from FiberCell
(Frederick, MD). Pyrazinamide, isoniazid, rifampin, and acetaminophen
(APAP) were purchased from SIGMA (USA).
Liver enzymes such as aspartate transaminase (AST), alanine trans-
aminase (ALT), and lactate dehydrogenase (LDH) were measured
using Vitros 250 system. Change in the Cyp3A4 was measured using
RT-PCR while Bioplex Multiplex System (Bio RAD, USA) was used for
measurement of interleukin 8 (IL-8), monocyte chemotactic protein 1
(MCP-1), vascular endothelial growth factor (VEGF), and platelet-
derived growth factor (PDGF).
2.3.1. Three Dimensional Organotypic Liver Hollow Fiber Model of Mtb
The HFS-TBmodel consists of (a) a peripheral or pharmacodynamics
compartment for theMtb inoculum and (b) a central drug containing or
pharmacokinetic compartment (Srivastava and Gumbo, 2011). In thepast, we developed a HFS models of extracellular Mtb and intracellular
Mycobacterium avium complex (MAC) in which concentration-time
proﬁles of antibiotics encountered in adult patients were recapitulated
(Deshpande et al., 2010a; Deshpande et al., 2010b; Gumbo et al.,
2004; Gumbo et al., 2007a; Gumbo et al., 2007b; Gumbo et al., 2009a;
Schmalstieg et al., 2012; Srivastava et al., 2010; Srivastava et al.,
2011a). For pediatric disseminated TB, we infected THP-1 macro-
phages with Mtb. We further improved the intracellular HFS-TB
model for assessment of hepatotoxicity by retroﬁtting 3D liver
organoid cultures. The 3D-liver cultures were made of 106 HEpG2
embedded in alginate beads (total volume of 400 μL), which were
cultured in 3D perfusion in the 3DKUBE™ (KIYATEC, Greenville,
SC). The 3D KUBES were ﬁtted in to the ﬂow path of the HFS between
the central reservoir, where the drug is delivered, and peripheral
compartment. The drug was infused into the central compartment
via a syringe pump at a predeﬁned rate to achieve the peak concen-
trations and systemic clearances encountered in humans treated
with the equivalent doses.
Several preparatory experiments demonstrated that monocytes
would only live for a few days if the virulentMtbH37Rv was used to in-
fect the macrophages; however the isogenic strain H37Ra produced a
stable infection for over 4weeks. For infection, prior to each intracellular
Mtb study, THP-1 monocyte cells were grown in RPMI 1640 medium
supplemented with 10% FBS to a density of 1.5 ∗ 106 CFU/mL. Next, log
phase Mtb culture was at a bacterial density of 1.5 ∗ 107 CFU/mL was
co-incubated with the THP-1 cells for 6 h at 37 °C under 5% CO2, giving
a multiplicity of infection of 1:10. Infected THP-1 cells were then
washed twice with warm RPMI 1640 by centrifugation at 100×g for
5 min and examined in a hemocytometer for cell counts and viability
after staining with trypan blue. The THP-1 cell counts before and after
infection with Mtb were also veriﬁed with an automated cell counter
(Sceptor, EMD Milipore). We then inoculated the peripheral compart-
ment of each HFS with 20 mL of infected THP-1 cells (3.0 ∗ 107 cells/
HFS) into the peripheral compartment of the HFS.
2.4. Intracellular HFS-TB Studies Using Pediatric Pharmacokinetics of
Pyrazinamide for Efﬁcacy and DILI
The THP-1 cells were infectedwithMtb as described above and inoc-
ulated into the HFS retroﬁtted with 3D KUBES. The systems were then
treated with one of the ﬁve pyrazinamide doses (0, 1/4, 1/2, 1, 2, and
4 times standard dose) administered daily for 28 days via computer-
controlled syringe pumps, mimicking a 6 h half-life as encountered in
babies (Donald et al., 2012). As a positive control for DILI, we utilized
daily APAP (t1/2 = 3 h) with a goal of 4 h post dose levels of
N150 mg/L, known to cause DILI in children based on the Rumack-
Matthews monogram (Rumack and Matthew, 1975; Rumack et al.,
1981). RPMI 1640 supplemented with 10% FBS was infused using com-
puter controlled peristaltic pump at a predeﬁned rate to maintain the
THP-1 monocyte and HepG2 cells in the 3D KUBES and to achieve the
half-life of each drug in eachHFS. Samples from the peripheral compart-
mentwere collected on day 0, 7, 14, 21, and 28, washed twice with nor-
mal saline to remove any carry over drug, and cultured onMiddlebrook
7H10 agar supplemented with 10% OADC to enumerate the total bacil-
lary burden. To conﬁrm the intended pharmacokinetic proﬁle of the
drug achieved in each system, the central and peripheral compartments
were sampled seven times over 24 h tomeasure the drug concentration.
Samples from the central compartment and the 3D KUBES were also
subjected to measure the level of AST, ALT, LDH, Cyp3A4, IL-8, MCP-1,
VEGF, and PDGF to analyze the DILI on days 0, 2, 5, 21 and 26.
2.5. Role of Pyrazinamide in the Combination Therapy Against Intracellular
Mtb
We performed HFS studies to determine the extent of pyrazinamide
contribute to the standard three drug (isoniazid, rifampin, and
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either dual regimen (isoniazid–rifampin) or triple regimen (isoniazid–
rifampin–pyrazinamide) over 28 days, in triplicate. The systems were
sampled at predetermined time point for enumeration of the total
bacterial burden as described above. In addition the concentration-
time proﬁle of the drugs was conﬁrmed by sampling the central and pe-
ripheral compartments seven times over 24 h and concentrations of the
isoniazid, rifampin, and pyrazinamide were measured using the previ-
ously validated method (Gumbo et al., 2009a; Srivastava et al., 2011a;
Srivastava et al., 2011b).
2.6. Pyrazinamide Activity Against Extracellulat Mtb and Effect of Cytokines
on Pyrazinamide Efﬁcacy Against Intracellular Mtb
Weexamined the effect of several concentrations of pyrazinamide (1/
8 to 8× of the standard dose) against extracellularMtb in Middlebrook
broth that had been acidiﬁed to pH 5.8 (Gumbo et al., 2009b) over a pe-
riod of 14 days. On day 14 the cultureswerewashed twice to remove any
carry over drug, serially diluted and cultured on Middlebrook agar, and
incubated at 37 °C with 5% CO2 for at least 21 days before the colonies
were counted.
It has been argued that pyrazinamide works against intracellular
Mtb in humans in concert with secreted IFN-γ by granulomas; indeed
in the BALB/c mouse model of TB in whichMtb is predominantly intra-
cellular pyrazinamide shows dramatic efﬁcacy (Ahmad et al., 2011). To
test this hypothesis, we ﬁrst activated the THP-1 macrophages using
phorbol myristate ester (PMA) and then infected the adherent cells
withMtb as described above, and performed the dose–response study,
with the same dose ranges as used for the extracellular experiments,
in the presence of IFN-γ at a concentration of 5 μg/mL and the IFN-γ an-
tagonist dexamethasone at 1 μM concentration. The study was per-
formed twice. Next, we repeated the experiment but this time with
TNF-α at a concentration of 5 ng/mL, and a TNF-α antagonist (rabbit
anti-human TNF-α) at 10 μg/mL. The experiment was performed
twice. Finally, the same study was repeated with pyrazinamide (but
no cytokines), but instead of adherent THP-1 cells we infected adherent
mouse macrophage cells, the J774A.1 cell line, originally isolated from
BALB/c mice.
2.7. Host-pathogen RNA-Seq
Mtb cultures grown in Middelbrook broth on day 4 of logarithmic
phase growth and from semidormant bacteria on day 4 of incubation
in broth at pH 5.8 (Gumbo et al., 2009a), were treated with
pyrazinamide concentration of 294 mg/L (NEC80) for four days, and
RNA extracted. Next, during the combination therapy hollow ﬁber stud-
ies above, samples for enumeration of Mtb cultures described above
were used to extract RNA on the various sampling days described above.
Following extraction, the RNA samples were depleted of ribosomal
RNA, and subsequently used for sequencing library preparation for
whole transcriptome analysis using TruSeq RNA sample preparation
v2 kit (Illumina Inc. San Diego, CA). The size selected libraries were
quantiﬁed by PicoGreen assay (Life Technologies, Carlsbad, CA) and vi-
sualized with an Agilent Bioanalyzer using a DNA 1000 kit (Agilent
Technologies, Waldbronn, Germany). This was followed by cluster gen-
eration step in an Illumina cBOT TM instrument following the
manufacturer's protocol using a TruSeqTM SR Cluster Kits v3 (Illumina
Inc.; San Diego, CA). Finally 6 indexed libraries were loaded into each
ﬂow cell lane and sequencing (75 bp single end) was performed on an
Illumina HiSeqH2000 instrument (Illumina, Inc.) according to the
manufacturer's protocol. Multiplexed single-read runs were carried
out with a total of 57 cycles per run (including 7 cycles for the index se-
quences). Illumina HCS 2.0.12/RTA 1.17.21.3/SAV 1.8.20 Software was
used for real-time image processing and base calling.
The data was analyzed for the quality control of the reads, and align-
ment of reads was made to Mtb reference genome NC_000962,and HumanRefSeqBuilt37 (GRCh37p13). CLC Genomic workbench
(v 8)was used for alignment of sequencing reads. The datawas normal-
ized and statistical test was performed to ﬁnd the signiﬁcantly differen-
tially expressed genes (DEG) with statistically signiﬁcant p value
(b0.05) with Bonferroni post-test correction. We deﬁned DEG as ≥2.0-
fold change with a signiﬁcant p-value b 0.05. Analyses were performed
using CLC Genomics workbench 8.0.
2.8. Imaging for Changes in the Intracellular pH
THP-1 and J774A.1 cells were infectedwithMtb, as described earlier.
At 24, 48, 72 and 168 h post infection, cells werewashed and stained for
30 min with pHrodo Green as per the manufacturer's protocol (Life
Technologies, USA). The stained cells were ﬁxed with 4% formalin for
15 min and subjected to ﬂuorescent microscopy (Cytation 3 Cell Imag-
ing Multi-mode Reader, BioTek Instruments Inc., USA) to determine
the changes in the intracellular pH as relative increase or decrease in
the ﬂuorescence intensity. We used the FITC ﬁlter sets with excitation
and emission at 509/533. Images were taken at 10-times magniﬁcation
and Gene5 data analysis software was used for image acquisition and
analysis (BioTek Instruments Inc., USA). In addition to the qualitative
analysis of the images for the changes in the green ﬂuorescence, we
also recorded the number of cells, size and mean ﬂuorescence values
for each sample to compare the differences between the uninfected
and Mtb infected cells. The experiment was performed in triplicate on
three different occasions. In order to make sure that ﬁndings were not
simply due to the fact that Mtb H37Ra was avirulent, we repeated the
studies with Mtb H3Rv, with the same mammalian cell lines, with up
to 72 h post-infection observation.
2.9. Statistical Analysis for the Laboratory Experiments
Two-way analysis of variance (ANOVA) was used to compare bacte-
rial burden at each time point in GraphPad Prism version 6.0 (GraphPad
Software, CA). Linear regression was used to compare the kill slopes of
different treatment regimens and for dose-response studies we used
the inhibitory sigmoid Emax model.
2.10. Recruitment of Children in India and Artiﬁcial Intelligence Analyses
Children were enrolled for pharmacokinetic analysis and clini-
cal outcome ascertainment in two prospective studies in India
(Ramachandran et al., 2013; Ramachandran et al., 2015). Recruit-
ment details and ethical considerations for the children were as
published before (Ramachandran et al., 2013; Ramachandran
et al., 2015). Brieﬂy, parents or guardians gave informed written
consent for all children ≤6 years-old, while all children aged
N7 years gave assent. The study protocols were approved by the In-
stitutional Ethics Committees of each study site. Children were re-
cruited at multiple hospitals and sites in India, as speciﬁed before
(Ramachandran et al., 2013; Ramachandran et al., 2015). Tubercu-
losis case deﬁnitions and clinical care were according to India's Revised
National TB Control Program (RNTCP), as were deﬁnitions of outcome
such as treatment completion, failure, and non-adherence. Individual
drugs were made available for the entire treatment duration. The treat-
ment doses were as follows: pyrazinamide 30–35 mg/kg, rifampin
10mg/kg, isoniazid 10 mg/kg, ethambutol 30 mg/kg, and streptomycin
15mg/kg, three times aweek by parent/guardian. Childrenwere admit-
ted for blood draw of samples for pharmacokinetic analyses; treatment
was administered under supervision of a study nurse, whowatched the
children swallow themedicines, afterwhich bloodwas drawn at 0 (pre-
dose), 2, 4, and 8 h. HIV-infected children were treated with antiretro-
viral therapy as recommended by the National AIDS Control Organiza-
tion (NACO) guidelines. Drug concentration assays were as described
before (Ramachandran et al., 2013; Ramachandran et al., 2015).
Patients were followed for at least 6 months.
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bles to identify predictors of outcome in TB, as described in full else-
where (Gumbo et al., 2014b; Gumbo et al., 2014a; Pasipanodya and
Gumbo, 2013). We deﬁned good clinical outcomes in children as com-
pletion of therapy that required no further treatment.We excluded chil-
dren who were non-adherent from the deﬁnition of poor outcomes
since we have found elsewhere that non-adherence is a poor surrogate
of poor microbial or clinical outcomes (Pasipanodya and Gumbo, 2011;
Pasipanodya and Gumbo, 2013; Srivastava et al., 2011a). We speciﬁed
16 potential predictors, including all clinical and demographic factors,
measures of nutrition, HIV-coinfection, and isoniazid, rifampicin, and
pyrazinamide concentrations. The classiﬁcation and regression tree
(CART) algorithms search through all these potential predictors and
perform binary recursive partitioning in order to classify patients into
two groups of maximum homogeneity at a node, the ﬁrst being the pri-
mary node. The process continues to create daughter nodes and
branches, hence trees. A variable importance score was assigned to
each subsequent daughter node, which was a percentage of how
much the daughter nodes improved when added to the primary node.
We employed Gini criterion function for splitting nodes and attaining
the minimum cost tree. Finally, the deep trees created were pruned to
improve the predictive value of the models by using the receiver oper-
ator curve (ROC) score. CART employs a cross validation procedure in
which new data sets are created by randomly splitting themain dataset
into learning and test databases, and calculating the test ROC based on
the best tree chosen. However, CART is notorious for over ﬁtting and a
bias for multi-way splits. Bootstrap aggregating (bagging) is an ensem-
ble of algorithms that reduce variance and overﬁtting, reduce bias, and
create stable trees (Breiman, 1996). Random Forest performs this func-
tionby averaging out theCART decision training trees (i.e., by trees “vot-
ing”), to give a modal output (Breiman, 2001). We validated the
Random Forest model by setting aside a third of the data, then used
the area under the ROC to compare models after running 300 to 500
classiﬁcation trees. We utilized Salford Predictive Miner System soft-
ware (San Diego, CA) for the AI analyses.
3. Result
3.1. An Intracellular Mtb and 3D Organotypic Liver Hollow Fiber Co-culture
System
First, we compared the effect of static concentrations of
pyrazinamide and APAP (positive control), at the same 24 h area
under the concentration-time curve (AUC) concentrations encountered
in patients, on 3D-liver cultures compared to HEpG2 monolayers, in
triplicate. CYP3A4was chosen for study because it is responsible forme-
tabolizing more than 50% of all of all pharmaceutical compounds in
humans, including APAP (Sevrioukova and Poulos, 2015). Fig. 1a
shows quantitative PCR results for the Cytochrome P450 3 A4
(CYP3A4). HepG2 cells had a four-fold increase in CYP3A4 expression
in 3D co-culture as compared with the monolayer (Fig. 1a). The intent
of the experiment was not to examine the cytochrome P450-mediated
metabolism of pyrazinamide, but instead this was a surrogate readout
of the 3-Dmodel's overall metabolic capacity as a better approximation
of in vivo events, whichwas higher than inmonolayers. These 3DKUBEs
were then utilized asmodules to examine toxicity in theHFSmodel.We
retroﬁtted pairs of engineered 3DKUBEs into themedia ﬂow path of the
central compartment of each HFS, are shown in Fig. 1b–c. The infected
human-derived THP-1 cells and the hepatocytes were viable for up to
4 weeks.
3.1.1. Pyrazinamide Dose-effect Studies for Efﬁcacy and DILI Using Pediatric
Pharmacokinetics
Next, we examined the effect of ﬁve pyrazinamide doses and one
APAP dose. Each HFS had four 3DKUBEs in the ﬂow path, which were
exposed to pyrazinamide concentration-time proﬁles shown in Fig.2a.The ﬁgure shows good recapitulation of serum concentration-time
proﬁles of pyrazinamide in children in each HFS replicate. The
pyrazinamide elimination rate constant was 0.117 ± 0.011 h−1,
which is identical to that encountered in children b6 years old and
translates to a half-life of 5.92 ± 0.58 h. Each HFS was sampled
once every 7 days for AST, ALT, and LDH concentrations, with results
shown in Fig.2b. APAP, the DILI positive control based on the
Rumack-Matthews nomogram target (Rumack and Matthew,
1975), was associated with at least 3-fold change for LDH
(p b 0.05) and increase in both AST and ALT. On the other hand,
there was actually a slight decrease in AST (r2 = 0.21) and ALT
(r2 = 0.32) with increased pyrazinamide dose. This was veriﬁed
not be due to decreased numbers of liver cells from toxicity. Cyto-
kine analysis on the cell culture supernatant from the 3D-liver mod-
ules was performed at different time points; results for selected
cytokines such as IL8, MCP-1, VEGF, and PDGF, are shown in Fig.
2c–f. The ﬁgures show that the pattern of IL-8 and VEGP for APAP
treated HFS differ from non-treated controls. The results mean that
for pyrazinamide doses up to 100 mg/kg human equivalent (4
times standard), there was no evidence of increased DILI or cytokine
release consistent with liver damage, while the positive control
APAP demonstrated DILI by these criteria.
The number of viable macrophages in the peripheral compartments
of the HFS replicates at each sampling time point are shown in Fig. 2g,
which demonstrates continued viability up to 4 weeks. TheMtb burden
is shown in Fig.2h, which demonstrates that for both the standard and
high dose pyrazinamide, the day-to-day Mtb burden was no better
than sham treatment. Thus, despite high doses, whose concentrations
were validated by direct measurement, pyrazinamide daily doses did
not kill intracellular Mtb in the HFS over 28 days of experiment. The
minimum inhibitory concentration (MIC) of pyrazinamide against the
Mtb isolate, examined at pH 5.8, was 25 mg/L on several occasions, so
that failure is not due to intrinsic pyrazinamide resistance of the labora-
tory strain we used.
3.2. Interferon-γ and TNF-α Do Not Enhance Efﬁcacy or Potency of
Pyrazinamide
In order to determine if IFN-γ or TNF-α improved pyrazinamide ef-
fectiveness, we ﬁrst examined the effect of several concentrations of
pyrazinamide against extracellularMtb in Middlebrook broth that had
been acidiﬁed to pH 5.8, with results shown in Fig.3a. The ﬁgure
shows concentration-dependent killing of Mtb by pyrazinamide with
14 days incubation; the pyrazinamide markedly killedMtb by about 2-
log below day 0 burden (stasis). Based on inhibitory sigmoid Emax
model the mean (±standard error) concentration mediating 50% of
maximal kill (potency) was a 51.95 ± 15.79 mg/L and maximal kill (ef-
ﬁcacy) was 2.93 ± 0.46 log10 CFU/mL on day 14.
Next, we activated THP-1 macrophages and performed the same
dose–response study with and without IFN-γ or the IFN-γ inhibitor,
with day 14 results shown in Fig.3b. There ﬁgure shows that there
was no net kill of Mtb, with maximal effect occurring at bacterial bur-
dens higher than on day 0, which means bacteria treated with
pyrazinamide actually grew. Comparison of inhibitory sigmoid Emax re-
gression ﬁts revealed that the three conditions (pyrazinamide alone
versus with IFN-γ versus with IFN-γ inhibitor) shared the EC50 of
30.24 ± 2.72 mg/L and the slope (Hill factor) of 3.03 ± 0.79, while the
Emax was actually higher without IFN-γ (1.05 ± 0.13 log10 CFU/mL)
compared to with IFN-γ (0.80 ± 0.08 log10 CFU/mL). Similarly, supple-
mentation with either TNF-α or a TNF-α inhibitor resulted in no de-
crease in microbial burden below stasis (Fig. 3c). All three treatment
conditions shared the 3 parameters of EC50, Hill factor, and Emax. Thus,
pyrazinamide had no antimicrobial effect in activated and infectedmac-
rophages on 6 occasions (each experiment was performed twice), and
neither did IFN-γ nor TNF-α improve that. On the other hand, since
pyrazinamide killsMtb in BALB/c mice, we performed the same 14 day
Fig. 1. The intracellular Mtb hollow ﬁber model of tuberculosis with 3 dimensional organotypic liver modules. (a) 3D KUBES versus a monolayer of HepG2 cells (2-D) were treated with
either pyrazinamide 60 μg/mL, or APAP150 μM, or LPS 1 μg/mL; RNA was extracted and subjected to quantitative PCR for CYP3A4. There was higher expression of CYP34A in 3D KUBES
compared to 2D cell model (p = 0.0001). Error bars are standard deviation. The experiments were done in triplicate and performed twice to conﬁrm the ﬁndings. (b) Schematic
diagram of the HFS showing retroﬁtted 3D KUBEs in the media ﬂow path. (c) An image of 3D KUBEs attached to the ﬂow path of the hollow ﬁber model system.
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cells for human derived THP-1 cells. Fig.3d shows that pyrazinamide
killed Mtb in the murine-derived macrophage cell-line below stasis.
The EC50 was 8.65 ± 2.02 mg/L, which is several fold-lower that of
pyrazinamide against extracellular Mtb at pH 5.8, while Emax was
lower at 1.47 ± 0.14 log10 CFU/mL, but the Hill factor of 1.18 ± 0.44
was similar to results in Fig.3a. Thus pyrazinamide is effective inmurine
macrophages and extracellularly at pH 5.8, but not in activated human-
derived cells.
3.3. Lack of Pyrazinamide-effect in Combination Therapy
Pyrazinamide could still kill intracellularMtb when in combination
regimens while demonstrating no efﬁcacy as monotherapy due to
higher order non-linear interactions between pyrazinamide and rifam-
pin seen in adults (Chigutsa et al., 2015; Pasipanodya and Gumbo,
2013). Therefore, we examined the effect of the three-drug regimen of
isoniazid, rifampin, and pyrazinamide (triple-regimen) and comparedit to the two-drug regimen of isoniazid and rifampin (dual) in the HFS
model. Pyrazinamide was administered at double the standard dose.
The concentration-time proﬁles achieved are shown in Fig. 4a–c,
which demonstrate good pharmacokinetic recapitulation of each drug.
The ﬁgures also demonstrate the capability to produce different half-
lifes of drugs in the same HFS, an aspect vital to studying the effects of
combination therapy regimens. Importantly, we also simultaneously
measured the intracellular concentration-time proﬁle of each of the
three antibiotics in themacrophages in the HFS. Fig. 4a–c demonstrates
that in fact, at steady state, after 4weeks of daily dosing, the intracellular
concentration-time proﬁles of rifampin, isoniazid and the pyrazinamide
were dramatically higher inside macrophages. For rifampin, the elimi-
nation rate constant (and hence half-life) was similar between the in-
tracellular and extracellular pharmacokinetics (0.17 versus 0.19 h−1),
as was the case with isoniazid (0.19 versus 0.21 h−1) [p = 0.99]. On
the other hand, pyrazinamide elimination constant was 0.253 ± 0.112
versus 0.136± 0.005 h−1and volumewas 8.379± 3.310 × 10−2 versus
38.8 ± 0.40 × 10−2 L for intracellular versus extracellular (central
Fig. 2.Assessment of pyrazinamide DILI and efﬁcacy in theHFS. (a) Concentration time proﬁle of each of theﬁve pyrazinamide doses as achieved in theHFS. Shown are the actual observed
concentration-timeproﬁles for eachdose, demonstrating faithful recapitulation of pyrazinamide pharmacokinetics in pediatric circulatory system in eachHFS replicate. (b)When eachHFS
was sampled every seven days to measure the changes in LFTs, there was virtually no difference between different pyrazinamide doses and untreated controls in enzyme concentrations.
However, the hepatotoxicity by APAP was evident based on the signiﬁcantly higher AST, ALT, and LDH than untreated controls. (c–f) Levels of IL-8, MCP-1, VEGF, and PDGF measured on
different days as indicators of hepatotoxicity. Statistically signiﬁcant increases in levels of IL-8 and VEGF (p b 0.05) were encountered with APAP, known to cause hepatotoxicity, but not
with any pyrazinamide dose. (g) Numbers of the viable THP-1 cells in the HFS were not signiﬁcantly different between control, pyrazinamide and APAP treatment (p N 0.05). (h)
Comparison of the kill curves of pyrazinamide dose up to four times of the standard human equivalent dose shows that all doses failed to control the growth of intracellularMtb.
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concentrations on the natural logarithm scale, which reveals a differ-
ence in the slopes, indicative of differences in half-life of 3.20 versus5.14 h. This suggests that an active process eliminates or metabolizes
pyrazinamide from mammalian cells faster than it is washed out
of the HFS; and that intracellular milieu creates a different
Fig. 3. Effect of IFN-γ on intracellular activity of pyrazinamide. In each experiment, cultureswere treatedwith pyrazinamide concentrations shown for 14days. Therewere 3 replicates, and
each study was performed. Weighting was by 1/Y2. (a) Pyrazinamide killed extracellularMtb at pH 5.8, as shown by maximal kill below the day 0 bacterial burden (stasis). (b) In THP-1
human-derived cells treatedwith either pyrazinamide alone, or with IFN-γ or its inhibitor, theMtb grew above stasis. (c) Similar results were encounteredwith exogenous TNF-α or TNF-
α antagonist. (d) Pyrazinamide killed the intracellularMtb in J774A.1 mouse macrophage cell line below stasis.
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tem. Fig.4d demonstrates the change in bacterial burden with time for
the dual versus triple regimens. The Fig.4d shows that there was no dif-
ference in kill-rates between the triple versus dual regimens. Thus,
pyrazinamide did not contribute to microbial kill of the intracellular
Mtb by the combination regimen during the 28-day experiment, despite
achieving higher intracellular peak concentrations and 0-24 h AUCs. The
failure of therapy is therefore not due to achieving poor drug concentra-
tion, but suggests that some intracellular processmay be limiting the ef-
fectiveness of pyrazinamide.
3.4. Lack of Pyrazinamide Transcriptomic Signature in Intracellular Mtb
In order to identify the RNA gene-signature speciﬁc to pyrazinamide
exposure, we exposed extracellularMtb to pyrazinamide for 4 days, ex-
tracted RNA and performed RNA-Seq. There were 106 DEGs based on a
non-adjusted p-value: 61genes were up-regulated and 45 down-
regulated. The full list of genes and their expression is shown in Supple-
mentary Data Set 1. We compared this to the transcriptome of cultures
extracted fromHFS treatedwith either the dual or triple regimen. Fig.4e
shows that we were able to re-align the Mtb reads N90%of the
bacterium's genome in HFS contents from infected non-treated, dual,
and triple drug regimens. Fig.4f shows the reads that mapped to per-
centage of the human genome. We then sought to identify the 106-
gene pyrazinamide signature in the triple treatment regimen compared
to non-treated HFS contents. No single DEG from the 106-transcript
pyrazinamide exposure signature was identiﬁed in the triple therapy
regimen, even with a non corrected p-value. We also compared the
Mtb transcriptomeof thedual therapyHFS contents to the triple therapy
regimen to identify any DEGs between the dual versus triple drug regi-
mens. The transciptomes were virtually identical, with no single DEG to
differentiate the two regimens on p-value post-test correction. Thus,wefound no transcript evidence of effective pyrazinamide exposure in in-
tracellularMtb.
As regards to human genes, there were no DEGs identiﬁed between
dual and triple regimens, with post-test correction. When no post-test
correctionwas performed,which leads to a high false positive discovery
rate, there were 103 down-regulated and 118 up-regulated DEGs. Path-
way analysis of these DEGs using REACTOMEmapped to olfactory trans-
duction (15 genes), metabolic pathways (9 genes) and neuroactive
ligands (4 genes). We found no human gene signature indicative of in-
duction of pro-inﬂammatory pathways, nor a single DEG that mapped
to these pathways, in the three-drug regimen. Thus, we found no tran-
script evidence of induction of pro-inﬂammatory pathways in human
macrophage derived cell line, despite high intracellular pyrazinamide
concentrations.
3.5. Mtb Neutralizes the Phagosome Acid pH in Human But Not Mouse
Macrophages
In order to killMtb, pyrazinamide is ﬁrst activated by acidic condi-
tions; the relationship between pyrazinamide effect and pH is described
by the Henderson-Hasselbach equation, with betterMtb kill at low pH
(McDermott and Tompsett, 1954; Zhang et al., 1999).We hypothesized
that one reason for lack of pyrazinamidemicrobial kill could be that the
pH in infectedmacrophage phagolysosomes is neutralized byMtb over-
time, as proposed by Zhang et al. for cultures in test tubes (Zhang et al.,
2002). We exposedMtb to Middlebrook broth at pH 5.8 buffered using
acetic acid, as well as to the same broth at neutral pH with no buffer,
and extracted RNA for RNA-Seq after 4 days. Fig.5a demonstrates up-
regulation ofMtb genes which encode for urease enzymes that neutral-
ize acidic pH. We sought for the expression pattern of the same urease
genes in the Mtb infected PMA-activated THP-1 cells at the beginning
of infection (i.e., at the end of bacterial-macrophage co-incubation),
Fig. 4. Pharmacokinetic proﬁles and transcriptome of combination therapy. This experiment was performed twice. Concentration-time proﬁle of (a) isoniazid and (b) rifampin. (c) Given
the range of pyrazinamide concentrations from 15 to about 5000 mg/L, we used the natural log transformed concentrations for pyrazinamide in a linear regression. The pyrazinamide
concentrations demonstrate 2 different slopes, hence half-life, for pyrazinamide. (d) The dual drug regimen (without pyrazinamide) and the triple drug regimen (with pyrazinamide)
had the same kill rates and slopes in the HFS model of intracellular Mtb. Thus, pyrazinamide does not contribute to the microbial kill in this regimen, nor does it lead to faster
microbial kill rates.(e) HFS contents were subjected to RNA-Seq and sequences re-aligned against theMtb genome. The ﬁgure shows good overall coverage of theMtb genome in the
different HFS cultures. (f) The percentage of the reads that mapped to the human genome in contents from the dual control, dual-, and triple-drug regimen is shown; themeanwas ~77%.
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tion. There was up-regulation of some of these sameMtb urease genes
at the beginning of infection as was encountered in the extracellular
Mtb exposed to acidic pH, suggesting that at transcript level, that the
Mtb pH neutralization machinery was up-regulated (Fig. 5b). The
genes continued being up-regulated up to 7 days, as shown in Fig.5b.
Since this was host-pathogen RNA-seq, we were able to simultaneously
examine the humanmacrophage gene expression. Fig.5c shows the ex-
pression of human genes that encode cellular pH sensing proteins in
Mtb infected macrophages compared to non-infected macrophages.
Fig.5c shows the differential expression of genes encoding intracellular
pH proteins that are known to be down-regulated under acidic condi-
tions: TRPV1, PKD2L1, PKD2L2, CA2, CA3,and ATPV1B1(Ishimaru and
Matsunami, 2009; Karet, 2002; Nakanishi et al., 2010; Sherry et al.,
1994). These genes were down-regulated at the beginning of infection,consistent with low pH conditions, but the direction changed and there
was reversal by day 7 (Fig. 5c). On the other hand, COL8A1 is up-
regulated under acidic conditions (Bumke et al., 2003), as was the
case at the beginning of infection, but by day 7 was no longer signiﬁ-
cantly up-regulated (Fig. 5c).
In order to conﬁrm the RNA expression changes at the level of phe-
notype, we infected THP-1 cells as well as the mouse JA774A.1 cell line
with Mtb and directly measured intracellular pH changes using the
pHrodo Green dye. At 24 h post-infection, there were no differences in
the intracellular pH of infected and non-infected THP-1 cells. However,
Fig. 5d–g show that starting 72 h post infection therewas neutralization
of acidic pH in the human derived macrophage cell-line, but not in the
murine derived cell-line (Fig. 5f–g). The mean green ﬂuorescent inten-
sity in the non-infected THP-1 cells was 24,311 ± 1666 compared to
the 9976 ± 587 in the Mtb infected THP-1 cells at 72 h (p b 0.01,
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crease in pH. On the other hand, the mean ﬂuorescence intensity in
the non-infected J774A.1 cells was 24,425 ± 1122 versus 21,070 ±
28.50 inMtb-infected J774A.1 cells (p= 0.10, r2 = 0.82). Using the vir-
ulentMtb H37Rv, with observations up to 72 h revealed similar results
(shown in Supplementary Fig. 1). The ﬂuorescence intensity at 72 h
was 25,925 ± 3708 in J774A.1 cells alone compared to 21,069 ± 40
with Mtb-infection (p N 0.05), while in THP-1 cells alone it was
21,917 ± 1492 with Mtb infection (p b 0.005). Taken together, these
data mean that there is neutralization of the acid pH in infected
human macrophages with time, and since pyrazinamide is activated
by acid pH, this could be one reason for lack of efﬁcacy.
3.6. Translation of HFS Results to Children in the Clinic
Wewanted to conﬁrm if results from our HFS model translate to ac-
tual children with extrapulmonary TB treated with pyrazinamide-
containing regimens, based on prospective study from India
(Ramachandran et al., 2013; Ramachandran et al., 2015). The clinical
and demographic characteristics of the 81 children with
extrapulmonary TB are shown in Table 1. When children of all ages
were examined using the AI method of Random Forests, the most im-
portant predictors of good clinical outcome (out of the 16 the model
clinical, demographic, and drug concentration factors) were as shown
in Fig.6a. The highest r2 for the covariance of concentrations such as
AUC and peak concentration within each drug was 0.49, which was en-
counteredwith rifampin peak and AUC. Pyrazinamide, isoniazid, and ri-
fampin peak and AUC concentrations, in that order, were the most
highly ranked predictors of outcome (Fig. 6a). The ﬁndings are virtually
similar to our ﬁndings in adults with pulmonary TB (Pasipanodya et al.,
2013), which means the machine learning algorithms performed
adequately.
However, when the same analyses were conﬁned to children
b6 years old who had extrapulmonary TB (i.e., babies and toddlers),
the ﬁndings were as shown in Fig.6b. Only isoniazid peak concentra-
tions were the main drivers of good clinical outcome, followed by
weight-for-height Z score (a measure of malnutrition) which was
the terminal node. The r2 on cross-validation was 64% compared to
89% on the learn sample, which is reassuring. Based on frequentist
statistical inference, 8/14 (57%) children of these children who had
an isoniazid peak concentration less than 4.8 mg/L had good out-
comes, compared to 14/14 (100%) with concentrations N4.8 mg/L,
an odds ratio of 37.92 (95% conﬁdence interval: 1.89–761.1; p =
0.002). Speciﬁcally, pyrazinamide concentrations were no longer
drivers of good clinical outcome in toddlers and infants with
extrapulmonary TB, consistent with them playing a minimal to no
role in predicting outcome.
4. Discussion
The HFS for extracellularMtb in lung cavities of adult patients, which
has been qualiﬁed by the European Medicine Agency and received edi-
torial endorsement from the Food andDrug Administration (FDA), has a
forecasting accuracy of within 94% of the quantitative clinical values
such as optimal exposures (Gumbo et al., 2015a; Gumbo et al., 2015b;
Pasipanodya et al., 2015). Since theMtb in babies and toddlers is intra-
cellular as a result of poor immune containment, our model mimics
the same physiological condition of Mtb and the relative lack of anFig. 5. Intracellular pH ofMtb-infectedmacrophage. (a)Mtb urease genes were up-regulated un
Mtb urease genes after 6 h co-culture of the Mtb and THP-1 macrophages, i.e., at the end o
phagolysosome environment.(c) Macrophage genes encoding pH sensing proteins were do
which reversed on day 7 in theHFS. Similarly COL8A1, whose expression is in the opposite direc
of intracellular pH inMtb-infected THP-1 cells was conﬁrmed using the pHrodo Green staining.
infected THP-1 cellswas still acidicwhereas that of theMtb infected THP-1macrophageswas alk
post-infection, and even on day 7. (h) Fluorescence intensity versus the intracellular pH scale
Adopted from life Technologies product manual, cat#P35373.immune system in children. This co-perfused model permits repetitive
sampling to enumerate intracellular bacteria, macrophage viability,
and serial liver function tests, during exposure to dynamic
concentration-time proﬁles of the drugs speciﬁc to young children.
This allows for a direct pharmacometric-based translation of efﬁcacy
and toxicity from the laboratory to children (Pasipanodya and Gumbo,
2011). Since most of the drugs approved by FDA were tested for DILI
in adults, and the hepatotoxicity in children is identiﬁed essentially as
post-licensing surveillance, our model allows pre-clinical dose testing
for hepatotoxicity for the anti-TB compounds. Indeed, toxicity can be
examined not just for antibiotics, but for any pharmaceutical compound
intended for use in children.
We found a surprising lack of contribution to efﬁcacy from
pyrazinamide in the treatment of disseminated TB. Speciﬁcally, we
demonstrated the lack of pyrazinamide activity inside the human mac-
rophage cell line. The HFS allowed us to delineate two pyrazinamide
pharmacokinetic systems, interrelated, systemic versus intracellular,
or “wheels within wheels.” Thus, failure was not due to lack of good
pyrazinamide penetration into human macrophages, but likely due to
a non-acidic pH inside the Mtb-infected macrophages several days
post-infection. We found no enhancement of the pyrazinamide effect
after adding IFN-γ; nor induction of genes mapping to pro-
inﬂammatory immune pathways on pyrazinamide exposure (Manca
et al., 2013). Regardless, the reasonwhybabies and toddlers get dissem-
inated TB is lack of immune containment (i.e., they are effectively im-
munosuppressed), and thus we would expect little to no help for
pyrazinamide from the children's immune systems. This means
that pyrazinamide has to exert a direct antibiotic effect in order to
be effective. When all 81 children in our study were examined, in a
population dominated by older children (N65%) who often have a
pulmonary component of TB, pyrazinamide peak and AUC were the
most important predictors of outcome, as was the case in adults in
the past (Chigutsa et al., 2015; Pasipanodya et al., 2013). Which
one of the two, AUC or peak, is more important would require a sep-
arate experimental design. In the past we have found that in South
African children, there were low correlations between the peak con-
centration and AUC for rifampicin and isoniazid, similar what we
found here; the exception being pyrazinamide correlation between
AUC and peak which was moderate (Hiruy et al., 2015). The impor-
tant ﬁnding, however, is that when children b6 years old were exam-
ined, who are most likely to present with disseminated TB,
pyrazinamide was no longer a driver, and none of the pyrazinamide
concentrations had any variable importance score. This, lack of
pyrazinamide effect based on an agnostic AI algorithm, is consistent
with HFS ﬁndings for disseminated pediatric tuberculosis. These
ﬁndings demonstrate the importance of considering the differences
in pathological lesions and microbial physiology, between adults
and babies and young children. A regimen that speciﬁcally caters
for these differences could have a better possibility at shortening
therapy duration in disseminated tuberculosis.
Finally, we advance some molecular techniques such as host-
pathogen RNA-seq, especially given the high GC content of Mtb, and
the relative amounts of mammalian RNA to bacterial RNA: proverbial
needles in a haystack. Host-pathogen RNA-seq has hitherto been
discussed mainly as a theoretical possibility. We were able to map
RNA back to ~95% of the Mtb genome. This technique, together with
the repetitive sampling provided by the HFS, allows use of this “digital”
read count information as a pharmacodynamicmeasure for intracellularder acidic condition. (b) IntracellularMtb in HFS cultures shows up-regulation of the same
f macrophage infection and on day 14, demonstrating ongoing attempt to neutralize
wn-regulated at the end of the 6 h infection, consistent with an acidic intracellular pH,
tion, suggests change in the intracellular pH from acidic pH to neutral. (d–e)Neutralization
Representative images at 72 h post-infection indicate that the intracellular pH of the non-
aline. (f–g) InMtb infected J774A.1 cells therewas no change in the intracellular pH at 72h
[*, p b 0.05; **, p b 0.01; ***, p b 0.001].
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Table 1
Comparison of children's clinical and demographic characteristics by outcomes.
Total N = 81 Favorable n = 66 Unfavorable n = 15 p-Value
Gender Female n (%) 39 (48) 31 (47) 8 (53) 0.656
Male n (%) 42 (52) 35 (53) 7 (47)
HIV test results Negative n (%) 55 (68) 45 (68) 10 (67) 0.910
Positive n (%) 26 (32) 21 (32) 5 (33)
Disease site Extra-pulmonary 79 (98) 64 (97) 15 (100) 0.792
Pulmonary and extra-pulmonary 2 (2) 2 (3) 0
Treatment category New 54 (67) 44 (67) 10 (67) 1.00
Previously treated 27 (33) 22 (33) 5 (33)
Age Median (range) 8 (1.5, 14) 8 (1.5, 14) 7 (2, 14) 0.946
Fig. 6. Pharmacokinetic analysis and clinical outcome as predictors of treatment success. (a) The best predictors of treatment outcome in all 81 childrenwith tuberculosis using the clinical
data and machine learning algorithm were the peak and AUC of pyrazinamide, followed by isoniazid, followed by rifampin. Also identiﬁed were various measures of nutritional status,
based on Z-scores. (b) When only children b6 years old were analyzed using similar methods, the role of pyrazinamide as a predictor vanished, and only isoniazid concentrations and
Z-scores were still signiﬁcant.
136 S. Srivastava et al. / EBioMedicine 6 (2016) 126–138bacterial infections, in the context of dynamic drug concentrations. The
changes in drug concentrationwith time and the simultaneous changes
in RNA digital reads can then be utilized to build system equations that
would allowus to scale from the level of RNAdynamics to bacterial pop-
ulations to the whole child using the same type of inhomogeneous dif-
ferential equations we introduced 12 years ago aswell as those recently
introduced by others (Gumbo et al., 2004; Magombedze and Mulder,
2012; Magombedze and Mulder, 2013).Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.02.040.Competing Interests
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